Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 6Recurrence 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Blast Crisis 2Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Rhabdoid Tumor 1

Interventions

Mycophenolic Acid 7fludarabine phosphate 6Radiotherapy 6Cyclophosphamide 6Antilymphocyte Serum 6Rituximab 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Whole-Body Irradiation 4Tacrolimus 4Flow Cytometry 4Etoposide 4Cord Blood Stem Cell Transplantation 4Busulfan 4tanespimycin 3Methotrexate 3Melphalan 3Lenalidomide 3Bortezomib 3plerixafor 2nelarabine 2mogamulizumab 2aldesleukin 2Vincristine 2Polymerase Chain Reaction 2Photopheresis 2Moxifloxacin 2Magnetic Resonance Spectroscopy 2Immunosuppression Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sezary Syndrome × Panobinostat × Clear all
NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Novartis

Phase 2 Terminated
9 enrolled 6 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡